New drug combo aims to tame liver side effects of cancer immunotherapy

NCT ID NCT07663422

Not yet recruiting Disease control Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining mycophenolate mofetil (MMF) with prednisone can better treat liver inflammation caused by checkpoint inhibitor cancer drugs. The trial includes adults with moderate to severe immune-related hepatitis who need to pause their cancer therapy. The main goal is to see if liver function improves within 30 days while safely reducing steroid use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mycophenolate mofetil plus prednisone
What this could lead to: If successful, this combination could become a standard first-line treatment for immune-related hepatitis, allowing patients to better manage this side effect and potentially continue cancer therapy.
What could go wrong: This is a small Phase 2 study with only 31 participants, so results may not apply broadly. The treatment carries risks of infection and other side effects, and it may not improve liver function as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE-MEDIATED HEPATITIS IMMUNE-RELATED ADVERSE EVENT

More trials for these conditions

Other studies related to the condition(s) this trial covers.